• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在过去两年中,临床微生物学领域最相关的出版物有哪些?

What are the most relevant publications in Clinical Microbiology in the last two years?

机构信息

Emilia Cercenado, Servicio de Microbiología y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Dr Esquerdo 46; 28007 Madrid, Spain.

出版信息

Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):64-67. doi: 10.37201/req/s01.15.2023. Epub 2023 Nov 24.

DOI:10.37201/req/s01.15.2023
PMID:37997875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10793556/
Abstract

This minireview describes some of the articles published in the last two years related to innovative technologies including CRISPR-Cas, surface-enhanced Raman spectroscopy, microfluidics, flow cytometry, Fourier transform infrared spectroscopy, and artificial intelligence and their application to microbiological diagnosis, molecular typing and antimicrobial susceptibility testing. In addition, some articles related to resistance to new antimicrobials (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, and cefiderocol) are also described.

摘要

这篇综述描述了过去两年中发表的一些与创新技术相关的文章,包括 CRISPR-Cas、表面增强拉曼光谱、微流控、流式细胞术、傅里叶变换红外光谱以及人工智能及其在微生物诊断、分子分型和抗菌药物敏感性测试中的应用。此外,还描述了一些与新型抗菌药物(头孢他啶-阿维巴坦、美罗培南-维巴坦、亚胺培南-雷巴坦和头孢地尔)耐药性相关的文章。

相似文献

1
What are the most relevant publications in Clinical Microbiology in the last two years?在过去两年中,临床微生物学领域最相关的出版物有哪些?
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):64-67. doi: 10.37201/req/s01.15.2023. Epub 2023 Nov 24.
2
Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.产 OXA-48 型肠杆菌科细菌对亚胺培南/雷巴他定、美罗培南/沃巴坦和头孢他啶/阿维巴坦的敏感性。
Int J Antimicrob Agents. 2022 Oct;60(4):106660. doi: 10.1016/j.ijantimicag.2022.106660. Epub 2022 Aug 18.
3
Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.瑞士产碳青霉烯酶肠杆菌科细菌中头孢他啶-阿维巴坦、美罗培南-维巴坦和亚胺培南-雷利巴坦联合用药的疗效。
Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1145-1152. doi: 10.1007/s10096-023-04647-0. Epub 2023 Aug 11.
4
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔:一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
5
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.表型、基因型和断点:评估针对 OXA-48 的β-内酰胺/β-内酰胺酶抑制剂组合。
J Antimicrob Chemother. 2023 Mar 2;78(3):636-645. doi: 10.1093/jac/dkac425.
6
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性:一项为期两年(2019-2020 年)研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
7
Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.表型、基因型和断点:评估 OXA-48 对β-内酰胺/β-内酰胺酶抑制剂组合的作用。
J Antimicrob Chemother. 2022 Sep 30;77(10):2622-2631. doi: 10.1093/jac/dkac074.
8
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
9
Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.希腊产碳青霉烯酶肺炎克雷伯菌分离株的流行病学和头孢他啶-阿维巴坦、美罗培南-法硼巴坦、亚胺培南-雷利巴坦、依拉环素、硫酸普拉米星及对照药物的体外活性
Infection. 2022 Apr;50(2):467-474. doi: 10.1007/s15010-021-01735-1. Epub 2021 Dec 2.
10
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.中国台湾地区耐碳青霉烯类肠杆菌科细菌的体外药敏研究:亚胺培南/雷利巴坦、美罗培南/比阿培南、头孢他啶/阿维巴坦、头孢吡肟/他唑巴坦和其他新型抗生素的活性。
J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. doi: 10.1093/jac/dkab141.

本文引用的文献

1
CRISPR-Cas13a system: A novel tool for molecular diagnostics.CRISPR-Cas13a系统:一种用于分子诊断的新型工具。
Front Microbiol. 2022 Dec 8;13:1060947. doi: 10.3389/fmicb.2022.1060947. eCollection 2022.
2
Microfluidic chip and isothermal amplification technologies for the detection of pathogenic nucleic acid.用于检测病原核酸的微流控芯片和等温扩增技术。
J Biol Eng. 2022 Dec 1;16(1):33. doi: 10.1186/s13036-022-00312-w.
3
Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina.在 COVID-19 大流行期间,阿根廷出现了对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌 ST11,同时携带 KPC-31 和新型变体 KPC-115。
Microbiol Spectr. 2022 Dec 21;10(6):e0373322. doi: 10.1128/spectrum.03733-22. Epub 2022 Nov 29.
4
Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.在由产肺炎克雷伯菌碳青霉烯酶(KPC)的肺炎克雷伯菌引起的多克隆暴发中,解读对新型碳青霉烯类β-内酰胺酶抑制剂联合制剂的可变耐药性,该肺炎克雷伯菌对头孢他啶/阿维巴坦耐药。
Clin Microbiol Infect. 2023 Apr;29(4):537.e1-537.e8. doi: 10.1016/j.cmi.2022.11.011. Epub 2022 Nov 19.
5
Scaling up artificial intelligence to curb infectious diseases in Africa.扩大人工智能应用以遏制非洲的传染病。
Front Digit Health. 2022 Oct 21;4:1030427. doi: 10.3389/fdgth.2022.1030427. eCollection 2022.
6
NDM-35-Producing ST167 Highly Resistant to β-Lactams Including Cefiderocol.产 NDM-35 的 ST167 对包括头孢地尔在内的β-内酰胺类高度耐药。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122. doi: 10.1128/aac.00311-22. Epub 2022 Jul 11.
7
Validation of Fourier Transform Infrared Spectroscopy for Serotyping of Streptococcus pneumoniae.傅里叶变换红外光谱法对肺炎链球菌血清分型的验证。
J Clin Microbiol. 2022 Jul 20;60(7):e0032522. doi: 10.1128/jcm.00325-22. Epub 2022 Jun 14.
8
Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China.中国血液系统恶性肿瘤患者血流感染碳青霉烯类耐药肺炎克雷伯菌中高水平头孢地尔耐药的出现。
Microbiol Spectr. 2022 Apr 27;10(2):e0008422. doi: 10.1128/spectrum.00084-22. Epub 2022 Mar 24.
9
Evaluation of FASTinov Ultrarapid Flow Cytometry Antimicrobial Susceptibility Testing Directly from Positive Blood Cultures.从阳性血培养物直接评估 FASTinov 超快速流式细胞术药敏检测。
J Clin Microbiol. 2021 Sep 20;59(10):e0054421. doi: 10.1128/JCM.00544-21. Epub 2021 Aug 4.
10
SERS-based sensor for the detection of sexually transmitted pathogens in the male swab specimens: A new approach for clinical diagnosis.基于表面增强拉曼光谱的男性拭子标本中性传播病原体检测传感器:临床诊断的新方法。
Biosens Bioelectron. 2021 Oct 1;189:113358. doi: 10.1016/j.bios.2021.113358. Epub 2021 May 21.